Sign In
Buy AIFF
$1.65
-0.130 (-7.30%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF)
08:00am, Thursday, 09'th Oct 2025
NEW YORK , Oct. 9, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Firefly Neuroscience, Inc. (NASDAQ: AIFF) on behalf of the company's shareholders. The investigatio
KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions tha
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR' Platform
07:45am, Tuesday, 26'th Aug 2025
– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just
– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain's functional architect
Firefly Neuroscience to be Added to the Russell Microcap® Index
08:05am, Monday, 23'rd Jun 2025
– Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial In
– R esearch supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia –
A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisiti
Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSW
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) -
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
08:00am, Friday, 21'st Feb 2025
Extends cash runway well into mid-2026; no new/replacement warrants issued Extends cash runway well into mid-2026; no new/replacement warrants issued
Firefly Neuroscience Accepted into NVIDIA Connect Program
07:45am, Tuesday, 11'th Feb 2025
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform
- University of Waterloo's Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay
Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher
12:25pm, Tuesday, 14'th Jan 2025
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
07:45am, Tuesday, 14'th Jan 2025
Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients Measuring brain age with EEG and BNA™ could lead to a proactive an
Firefly Neuroscience Closes on Financing of up to $12.4 Million
09:00am, Tuesday, 31'st Dec 2024
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovativ
